Biotech announced that on February 10, 2025, the company signed an agreement with Intas to license exclusive commercial rights for BAT2506 injections in the US market to the other party, with a down payment and milestone payment of up to US$164.5 million. The agreement came into effect on February 26, 2025, and the company recently received a milestone payment of $2.25 million from Intas. As of the announcement date, the product has been approved for marketing in the US and Europe, and marketing applications have been submitted to drug regulatory agencies such as China and Brazil, and are currently under review.
Zhitongcaijing · 3d ago
Share
Listen to the news
Biotech announced that on February 10, 2025, the company signed an agreement with Intas to license exclusive commercial rights for BAT2506 injections in the US market to the other party, with a down payment and milestone payment of up to US$164.5 million. The agreement came into effect on February 26, 2025, and the company recently received a milestone payment of $2.25 million from Intas. As of the announcement date, the product has been approved for marketing in the US and Europe, and marketing applications have been submitted to drug regulatory agencies such as China and Brazil, and are currently under review.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending